Therapeutic options in anti-Jo-1 antisynthetase syndrome with interstitial lung disease: Comment on the article by Marie et al

Arthritis Care and Research

Volumn 65, Issue 9, 2013, Pages 1548-

  Cavagna, Lorenzo ^a   Caporali, Roberto ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; JO 1 ANTIBODY; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS;

ANTISYNTHETASE SYNDROME; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; TREATMENT RESPONSE;

ANTIBODIES, ANTINUCLEAR; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MYOSITIS;

EID: 84883339764     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22024     Document Type: Letter

References (9)

1. Marie I, Josse S, Hatron PY, Dominique S, Hachulla E, Janvresse A, et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013; 65: 800-8.
2. Sem M, Molberg O, Lund MB, Gran JT,. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009; 48: 968-71.
3. Marie I, Dominique S, Janvresse A, Levesque H, Menard JF,. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 2012; 106: 581-7.
4. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV,. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52: 2439-46.
5. Koreeda Y, Higashimoto I, Yamamoto M, Takahashi M, Kaji K, Fujimoto M, et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med 2010; 49: 361-9.
6. Cavagna L, Caporali R, Ali LA, Dore R, Meloni F, Montecucco C,. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol 2013; 40: 484-92.
7. Passadore I, Iadarola P, Di Poto C, Giuliano S, Montecucco C, Cavagna L, et al. 2-DE and LC-MS/MS for a comparative proteomic analysis of BALf from subjects with different subsets of inflammatory myopathies. J Proteome Res 2009; 8: 2331-40.
8. Cavagna L, Fusetti C, Montecucco C, Caporali R,. Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome [letter]. J Rheumatol 2010; 37: 1967.
9. Cavagna L, Prisco E, Montecucco C, Caporali R,. Pulmonary arterial hypertension in antisynthetase syndrome: comment on the article by Chatterjee and Farver [letter]. Arthritis Care Res (Hoboken) 2011; 63: 633-4.